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Abstract: 
The aim of this study was to examine whether changes in plasma androgen levels (total 
testosterone (T), free testosterone (FT), and dehydro-epiandrosterone-sulfate (DHEA-S)) induced 
by oral contraceptive (OC) use were related to changes in sexual interest or response or in mood. 
Sixty-one women provided blood samples and were assessed, using interviews and standardized 
questionnaires, prior to starting, and after 3 months on OCs (Ortho-Tricyclen®, Ortho-Tricyclen-
Lo®, or Ortho-Cyclen®, all containing the same progestagen, norgestimate). Significant 
decreases in T, FT, and DHEA-S were found after 3 months, although the extent of reduction 
was variable across women. There was some support for a relationship between the degree of 
reduction in total T and FT and the frequency of sexual thoughts after 3 months on OCs. 
However, some women had no loss of sexual interest in spite of substantial reduction in FT, and 
there was overall no evidence that reduction in FT affected enjoyment of sexual activity with a 
partner. The findings are consistent with the idea that some women may be more sensitive to 
changes in T than others. No relationship was found between negative mood, as assessed by the 
Beck Depression Inventory, and changes in T, FT, or DHEA-S. 





Since the introduction of oral contraceptives (OCs), the reported effects on sexuality and mood 
have been variable, with some women reporting improvement, some worsening and usually a 
majority reporting no change (Bancroft and Sartorius, 1990; Davis and Castaño, 2004). Negative 
changes in mood and sexuality, however, were found to be the strongest predictors of 
discontinuation in the first 6 months of OC use (Sanders et al., 2001), emphasizing the need to 
understand the mechanisms underlying these negative effects when they occur. 
Although many non-hormonal factors will influence a woman's reaction to OCs, there is some 
evidence that direct hormonal effects are relevant (Cullberg, 1972; Graham et al., 1995). 
Moreover, despite a strong association between well-being and sexual desire in OC users 
(Warner and Bancroft, 1988), and women in general (Bancroft et al., 2003), there is also some 
placebo-controlled evidence that negative effects of the pill on mood do not account for the 
negative effects on sexuality (Leeton et al., 1978; Graham and Sherwin, 1993), and need to be 
considered separately. 
 
It has been known for some time that OCs lower free testosterone (FT), partly because of 
suppression of ovarian steroid production and partly because of increased sex hormone binding 
globulin (SHBG), which results in a reduction in unbound or FT (Jung-Hoffman and Kuhl, 1987; 
Van der Vange et al., 1990; Janaud et al., 1992; Darney, 1995; Thorneycroft et al., 1999; Boyd et 
al., 2001). There is more limited evidence of a reduction in dehydro-epiandrosterone-sulfate 
(DHEA) and its sulfate (DHEA-S) (Coenen et al., 1996). The possibility that such hormonal 
changes might be related to mood or sexual negative side effects of OCs has been acknowledged 
(Bancroft and Sartorius, 1990; Davis and Castaño, 2004), but has received little research 
attention. 
 
At the present time there is considerable interest in the role of androgens in both the sexuality 
and well-being of women, with claims that testosterone (T) deficiency is an important cause of 
hypoactive sexual desire in women (e.g., Guay et al., 2004), and evidence that DHEA 
administration is effective in treating depression in men and women (Schmidt et al., 2005). The 
evidence of a role for T in the sexuality of women is, however, inconsistent (for review, see 
Bancroft, 2003). In a recent large-scale community-based survey of 1021 women aged 18–75 
years, Davis et al. (2005) found no association between the presence of sexual problems and low 
total or free T or androstenedione. Some association was found with low DHEA-S in pre-
menopausal women, although the majority of women with low DHEA-S did not report sexual 
problems. In the same study, however, an association between DHEA-S and well-being was 
found in premenopausal women (Bell et al., 2006). Ovaries are an important source of androgens 
in both pre- and postmenopausal women, and oophorectomy substantially lowers androgen levels 
(Judd et al., 1974). However, Nathorst-Böös et al. (1993) found that only 50% of women 
reported sexual problems following this procedure, suggesting that many women can experience 
substantial reduction in androgens without adverse sexual effects. On the other hand, in those 
women who experience such problems following oophorectomy, exogenous testosterone 
administration has been shown to be beneficial in placebo-controlled studies (e.g. Sherwin et al., 
1985; Shifren et al., 2000). A reasonable conclusion from this inconsistent evidence is that T has 
an enhancing effect on sexuality at least in some women. 
 
The commonest iatrogenic cause of lowered T in women is OC use. However, no studies have 
investigated whether there is a relationship between the reduction in T and changes in sexual 
interest or response or mood in women after starting on OCs. Furthermore, the limited evidence 
correlating T levels with mood or sexuality in women on OCs is restricted to women established 
on the pill; those who develop adverse effects are likely to have discontinued OC use, or at least 
switched to a different OC. It is noteworthy, however, that correlations between T and sexual 
interest have been more evident in women established on OCs than in non-OC users (Bancroft et 
al., 1980 and Bancroft et al., 1991; Alexander and Sherwin, 1993). This raises the interesting 
possibility, suggested by Alexander and Sherwin (1993), that the impact of varying T levels on 
women's sexuality will only be apparent when they are close to or below a certain threshold. This 
could explain why correlations between T and sexuality are observed in women taking OCs, if 
the T is reduced to levels around this threshold. In men, it is only when levels of T fall below a 
certain critical threshold (much higher than the top of the physiological range in women) that one 
sees clear correlations between T levels and sexual interest (Bancroft, 2003). However, the 
possibility of a low critical T threshold in women is difficult to reconcile with the clear evidence 
that supra-physiological levels of T following testosterone administration have beneficial sexual 
effects, with symptoms returning when levels have fallen but are still in the supra-physiological 
range, to an extent not evident in men (for review, see Bancroft, 2003). An additional 
complicating factor is that psychological problems might serve to obscure relatively subtle 
hormone–behavior relationships. One early study (Bancroft et al., 1980) compared 20 OC users 
complaining of low sexual desire, which they attributed to OC use, to 20 OC users without 
sexual problems. The levels of total T and SHBG were very similar in the two groups (FT was 
not estimated), but a correlation between T levels and sexual interest was only observed in the 
non-problem group. 
 
In this paper, we report the first study to measure changes in total T, FT, SHBG, and DHEA-S as 
well as mood and sexuality, in women starting on OCs. In view of the evidence cited above, we 
tested two hypotheses, both based on the assumption that androgens are relevant to OC-induced 
negative changes in sexuality and mood. The first postulates that it is the amount of reduction in 
T or DHEA-S that is relevant; women who experience loss of sexual interest or response, or 
worsening of mood, will show greater reduction in androgens than those with no negative or with 
positive changes on OCs. The second hypothesis, restricted to sexual effects, was based on the 
‘threshold’ possibility, discussed above. We predicted that levels of sexual interest or response 
will be affected when T or FT levels fall below a certain level. OCs, by substantially lowering T 
and FT levels, may effectively lower levels to below the threshold for some women. The specific 
prediction here is that relationships between T level and sexuality will become more apparent by 





There were two sources of recruitment: the main study and a sub-sample from an earlier study 
(Study 2). The main study was carried out in 2003–2004 and involved women starting on OCs, 
with random assignment to either Ortho-Tricyclen® (OTC) or Ortho-Tricyclen-Lo® (OTC-Lo). 
Both OTC and OTC-Lo have the same triphasic regime of progestagen (norgestimate 0.18, 0.215 
and 0.25 mg), but different levels of EE (OTC: 35 μg EE; OTC-Lo: 25 μg EE). The comparison 
of these two OC formulations will be reported in a separate paper (Greco et al., unpublished 
data). The principal aim of Study 2, carried out in 1998–1999, was to investigate predictors of 
early discontinuation of OC use and the main findings were reported by Sanders et al. (2001). A 
sub-group from this study (n=13) also provided blood samples during the pre-OC baseline 
month, and again during the 3rd month on OC. Due to problems with recruitment, this sub-
sample remained too small for separate analysis. Because the methods of recruitment and 
behavioral assessment were very similar in the two studies, these two samples have been 
combined for the analysis presented in this paper. Women in Study 2 had been randomly 
assigned to OTC or Ortho-Cyclen, a monophasic version with the same progestagen (0.250 mg 
norgestimate) and dose of EE as OTC. 
 
Recruitment to Study 1 was via advertisements posted at an Indiana University Health Center, 
the local Planned Parenthood Clinic, the campus newspaper and the Kinsey Institute website. For 
Study 2, recruitment was through the same University Health Center and Planned Parenthood 
Clinic. Inclusion criteria were 18 years of age or older, in a heterosexual relationship of at least 3 
months duration, and intending to use OCs for birth control for at least 3 months (1 year in Study 
2). Participants were also required to be university students as the blood sampling and medical 
screening took place at the University Health Center. Other inclusion criteria included: (1) 
menstrual cycle length of 21–35 days; (2) no history of diabetes or hypertension; (3) no current 
use of psychotropic medications, anti-neuroleptics, or daily antibiotics; (4) no current breast 
feeding; and (5) no pregnancy within the last 6 months. Women who had used OCs within the 
past 3 months (6 months for Study 2) or had known contraindications to OC use were excluded 
from the study. In the main study, participants received $60 for the initial interview and an 
additional $60 for the follow-up assessment, together with a free 3 months supply of OC. In 
Study 2, $50 was paid for the first assessment and $20 for each subsequent assessment. The 
Indiana University Institutional Review Board approved both studies and informed consent was 
obtained from all participants. 
 
In the main study, of the 106 women who were screened, 23 were ineligible, 23 were eligible but 
did not agree to participate, and 60 were enrolled in the study. While full follow-up data are 
given in the Results section, 48 of these 60 women provided data at the follow-up assessment, 
with blood samples being provided by 47. In Study 2, 107 women started, of whom 26 were lost 
to follow up and two became pregnant, leaving 79 women who were followed up for 12 months 
or who were assessed at earlier discontinuation. Thirteen of these women were in the sub-group 
involving blood sampling and were included in this report. The total sample size was thus 61 
women (48 from Study 1 and 13 from Study 2). This size of sample was considered acceptable 
since it would give 80% power at two-sided p<0.05 to detect a moderate correlation coefficient 
of 0.3 and, comparing two groups of 30 women each, a moderate/large effect size of 0.75 and a 
33% difference in proportions. 
 
Women were assessed prior to starting the OC and again after 3 months of OC use. For 
randomization, a computer-generated random sequence of numbers was used, with odd numbers 
assigned to one pill group and even numbers to the other. The randomization list was kept by a 
member of the research team (J.B.) who had no contact with any of the participants. As stated 
above, assessment was very similar in the two studies, but there were two differences, one 
involving assessment of sexuality, and the other, blood sampling. These will be explained below. 
 
2.2. Behavioral assessment 
After providing informed consent, study participants were interviewed and completed 
questionnaires before starting the OC. This assessment was repeated after three months of OC 
use; unless otherwise noted, all of the measures below were used in both Studies 1 and 2. 
 
2.2.1. Completed at initial assessment only 
2.2.1.1. Demographic and relationship questionnaire (DRQ) 
This self-report questionnaire obtained demographic information concerning age, employment 
status, marital status, education, racial/ethnic background, and income. It also assessed 
relationship status and commitment by asking about sexual exclusivity, length of relationship, 
and time spent together. 
 
2.2.2. Completed pre-OC and repeated after three months on OC 
2.2.2.1. Beck Depression Inventory (BDI) 
This well-validated instrument for measuring severity of depressive symptoms during the 
preceding week has 21 items, each of which is rated absent (0) to severe (3), with a total score 
range of 0–63. Scores from 0–9 are considered minimal, 10–16 mild, 17–29 moderate, and 30–
63 severe depression (Beck and Steer, 2000). Due to possible variation of mood through the 
menstrual cycle each woman completed the BDI on the first day of bleeding, to cover the 
premenstrual week and start of menses. 
 
2.2.2.2. Interviewer ratings of sexual function (IRSF) 
This is a semi-structured interview that has been used in a number of studies (Tyrer et al., 1983; 
Graham et al., 1995; Sanders et al., 2001) and has shown good inter-rater reliability. The IRSF 
was used to establish the frequency, over the preceding 3 months, of different types of partnered 
sexual activity as well as masturbation and, as a measure of sexual interest, of sexual thoughts. 
The question about frequency of sexual thoughts, our principal measure of sexual interest, was as 
follows: “Apart from the times that your partner approached you wanting to make love, how 
often have you found yourself thinking about sex with interest or desire?” The response 
categories for frequency are shown in Table 2. The IRSF also established the proportion of 
sexual acts with the partner during the 3 month period that were: initiated by the woman, 
experienced as pleasurable and enjoyable, associated with sexual excitement or arousal, and 
associated with orgasm (and various other aspects not reported in this paper). These proportions 
were rated on a six-point scale (0=never; 1=<25%; 2=about 25%; 3=about 50%; 4=about 75%; 
and 5=most or all occasions). 
 
An additional measure of sexual interest, the Sexual Desire Inventory (SDI-2) (Spector et al., 
1996) was used in the main study but not in Study 2. The SDI-2 measures two aspects of sexual 
interest: “Dyadic desire” (interest in sexual activity with another person) and “Solitary desire” 
(interest in engaging in sexual behavior by oneself e.g., masturbation). The correlations between 
the SDI and the IRSF for the main sample are presented here as they provide some evidence for 
convergent validity of the IRSF. The SDI Dyadic score correlated with the IRSF frequency of 
sexual thoughts, Spearman's correlation coefficient, rs=0.58, (n=48, p<0.001). The SDI Solitary 
score correlated with the IRSF-established frequency of masturbation, rs=0.91 (n=47, p<0.001). 
As participants in Study 2 did not complete the SDI, no further SDI data are reported in this 
paper. 
 
2.2.2.3. Side Effects Questionnaire (SEQ) 
This interviewer-administered assessment used in previous studies (Graham et al., 1995; Sanders 
et al., 2001) included a list of 18 items presented to the participant. Both direction (positive or 
negative) and extent of change (0, none; 1, mild; 2, moderate; and 3, marked) were recorded for 
each item. Positive scores could reflect reduction in a negative symptom (e.g., menstrual pain) or 
increase in a positive experience (e.g., increased sexual interest). Following the procedure used 
by Sanders et al. (2001), three mean summary scores were calculated for positive and negative 
changes; physical (headaches, feeling bloated, tender breasts, weight gain, nausea, aches and 
pains, skin changes, abdominal cramps, and tiredness); emotional (feeling better in mood, feeling 
worse in mood, more emotional, and less emotional); and sexual (loss of sexual interest, 
increased sexual interest, loss of sexual enjoyment, increased sexual enjoyment, and lack of 
vaginal lubrication). 
 
2.3. Hormonal assessment 
In Study 1, blood samples were taken ±2 days around ovulation in the last pre-OC cycle (based 
on their usual cycle length), and around pill days 12–14 during the third cycle of OC use. Each 
sample was assayed for total T, SHBG, % FT, FT and DHEA-S. In Study 2, four blood samples 
were taken at weekly intervals during the pre-OC cycle and again during the third OC cycle. All 
four blood samples for each cycle were assayed and means of the week 2 and week 3 samples for 
each woman for the pre-OC cycle (i.e., the two samples closest to ovulation) and for the third OC 
cycle were used in the analyses in this paper. 
 
Total T was measured with a Spectria Testosterone RIA kit obtained from Orion Diagnostica 
(Oulunsalo, Finland). Assay performance was monitored using control samples provided with 
the kit, and was within limits reported by the kit manufacturer. Assays were carried out in the 
laboratory of Professor Geoffrey Hammond who had previously published a study of women on 
OCs using the same direct RIA for total T, which had been validated by comparison with RIA 
preceded by chromatography (Hammond et al., 2003). 
 
Samples were analyzed in duplicate. If duplicate measurement exceeded 10% of the mean, 
samples were reanalyzed to ensure accuracy of measurement. 
 
SHBG concentrations were determined using a time-resolved immunoassay kit (PerkinElmer 
Life Sciences). Assay performance was monitored by inclusion of control samples provided by 
the kit manufacturer, and inter-assay variability for low and high SHBG concentration controls 
was within limits reported by the manufacturer. Values are expressed in nmol/L based on 
standards calibrated in terms of their steroid-binding capacity by Scatchard analysis. Samples 
were analyzed in duplicate at a 1:200 dilution. Samples containing very high concentrations of 
SHBG were re-analyzed at a 1:400 dilution to ensure accuracy of measurement. 
 
FT was calculated from a nomogram constructed using serum SHBG concentrations, and the 
percentage (%) FT measured by centrifugal ultra-filtration dialysis, in serum samples taken from 
normal female volunteers during treatment with OCs and untreated women during follicular and 
luteal phases of the menstrual cycle (methods and dataset reported in Hammond et al., 2003). 
The nomogram allows % FT to be predicted from SHBG values, and this value is then used to 
determine FT levels from total T measurements. 
 
Serum concentrations of DHEA-S were determined using a commercially available ELISA kit, 
based on a competitive immunoassay in which DHEA-S in the sample or in standards, competes 
with a DHEA-S-HRP conjugate for binding to anti-DHEA-S antibodies immobilized in the wells 
of a micro-titer well plate (Alpha Diagnostic International, San Antonio, TX, USA). The assay 
has been validated for human serum samples by the supplier, with intra-assay and inter-assay 
variabilities (% CV) of less than 12% over a wide range of values. 
 
2.4. Statistical methods 
Data were entered into Excel and transferred to Statistical Package for the Social Sciences 
(SPSS) version 13.0 (SPSS Inc, Chicago, Ill, USA) for statistical analysis. Categorical data are 
presented as N (%), and continuous data as mean (SD). Continuous data were categorized where 
appropriate so as to explore trends in the data and assess the linearity of any associations. To 
compare scores between the study groups, chi-squared (χ2) tests were used for categorical data 
and Mann–Whitney tests for continuous data. To compare scores over time, Wilcoxon matched 
pairs signed ranks tests were used. Associations between variables were assessed using the non-
parametric Spearman's correlation coefficient (rs). Statistical significance was taken at p<0.05 
throughout. However, because of the likelihood of Type 1 errors from multiple significance tests, 
95% confidence intervals (CIs) are used to express the uncertainty around the estimates. 
 
Nevertheless, with the number of correlations carried out, we cannot exclude the possibility that 




Of the 60 women who were recruited into Study 1, 12 (20%) (7 on OTC and 5 on OTC-Lo) did 
not complete the study. Four of these women were lost to follow-up (2 OTC, 2 OTC-Lo) and 
eight women discontinued. The reasons women gave for discontinuing were: lack of time (n=1; 
OTC); side effects (n=4; 2 OTC, 2 OTC-Lo); relationship ended (n=1; OTC); became pregnant 
(n=1; OTC-Lo); wanted to conceive (n=1; OTC). Combined with the 13 participants from Study 
2, this provided a sample of 61 for analysis in this paper. Characteristics of the participants and 
whether OCs had been used in the past are given in Table 1. Of the 61 participants, 30 women 
were assigned to OTC (24 in the main study, 6 in Study 2), 24 to OTC-Lo (all in the main study), 
and 7 to Ortho-Cyclen (all in Study 2). 
Table 1. 
Sample characteristics (n=61); values are given as n (%). 
Demographic/background variable Statistic 
Age in years, mean (SD) 20.1 (2.3) 
 Range 18–31 
Race⁎ 
 White 49 (80.7) 
 Asian 3 (5.3) 
 Black or African American 3 (5.3) 
 Other minorities 5 (8.7) 
Marital status 
 Single/never married 53 (86.9) 
 Living with partner, but not married 5 (8.2) 
 Married 3 (4.9) 
Demographic/background variable Statistic 
Median length of relationship (months) 11.5 
 Range 3–182 
First time OC user⁎ 34 (56.7) 
⁎ Due to missing data, n=60. 
There were no statistically significant differences in demographic characteristics between the 
participants in the two studies. The analyses were repeated excluding the 13 women recruited in 
the earlier study; the results were no different from the results in the whole sample. 
 
3.2. Descriptive data on behavioral variables 
3.2.1. Sexuality variables 
The IRSF ratings of frequency of sexual thoughts for the 3 months prior to starting the OC (Pre) 
and for the first 3 months on the OC (Post) are shown in Table 2. Although the proportion of 
women in each of the categories is similar for the two assessments and there were no significant 
differences between the frequencies at the two assessments, there was considerable individual 
variability, with 26 women (43%) reporting no change, 14 women (23%) reporting a decrease, 
and 20 women (33%) an increase in frequency of sexual thoughts (sexual interest). 
Table 2. 
Interviewer Ratings of Sexual Function (IRSF) before starting on OCs (pre), and after 3 months 
of OC use (post) (n=61)⁎. 
IRSF Pre n (%) Post n (%) n increased n decreased 
Frequency of sexual thoughts 20 14 
Absent/rare 0 (0) 2 (3.3)   
1–3 times/month 9 (14.7) 7 (11.7)   
At least once a week 11 (18.0) 7 (11.7)   
Several times a week 27 (44.3) 26 (43.3)   
At least once a day 14 (23.0) 18 (30.0)   
Frequency of sexual intercourse 12 16 
IRSF Pre n (%) Post n (%) n increased n decreased 
None in previous 3 months 4 (6.6) 1 (1.6)   
1–3 times/month 5 (8.2) 3 (4.9)   
Once a week 5 (8.2) 16 (26.2)   
2–3 times/week 35 (57.4) 32 (52.5)   
4 or>times/week 12 (19.7) 9 (14.8)   
⁎ Due to missing data, the n varied from 58 to 61. 
The IRSF ratings for frequency of sexual intercourse for the 3 months pre-OC (Pre) and the 3 
months of OC use (Post) are also shown in Table 2. Although the largest proportion of women 
showed no change from Pre to Post-OC, and there was no significant difference between the two 
assessments, once again there was considerable individual variability, with 16 women reporting a 
decrease and 12 an increase in frequency of intercourse. The IRSF ratings for other aspects of the 
woman's sexual experience (e.g., initiation, sexual enjoyment, sexual arousal) and the frequency 
of masturbation showed similar variability (not shown in Table 2). 
 
3.2.2. Mood 
The mean BDI score before starting on OCs was 9.3 (SD 6.8) and after 3 months on OCs was 8.1 
(SD 7.4). There were missing data for two women at baseline. Although group mean scores 
showed a slight improvement (reduction in BDI), there was considerable individual variation and 
no significant improvement (Mann–Whitney z=1.35, p=0.18). Taking change scores from −1 to 
+1 as indicating no change, 19 women (32%) fell in this category; 23 women (39%) showed 
improvement in mood (reduction in BDI score) and 17 women (29%) worsening in mood. 
 
In summary, for both sexuality and mood measures the comparison of the group mean pre–post 
assessments suggested little change; however, substantial proportions of women showed 
increases or decreases. 
 
3.2.3. Side effects 
Scores for each of the three summary scores (“physical”, “emotional”, “sexual”; see Section 2 
for items) were computed, indicating negative change, positive change, or no change from the 
pre-OC assessment (see Table 3). These data again highlight the marked variability in women's 
responses e.g., for sexual side effects, equal proportions of women showed positive, negative, or 
no change after starting OCs. 
Table 3. 
Proportion of women reporting negative change, positive change, or no change in physical, 
emotional, and sexual summary scores on the Side Effects Questionnaire (SEQ) (n=60); values 
are given as n (%). 
 Negative change Positive change No change 
Physical⁎ 31 (51.7) 21 (35.0) 8 (13.3) 
Emotional 24 (40.0) 17 (28.3) 19 (31.7) 
Sexual 20 (33.3) 20 (33.3) 20 (33.3) 
⁎ For list of items included in each summary score, see description of SEQ in Section 2. 
3.3. Hormone levels 
Levels of total T (nmol/L), % FT, FT (pmol/L), SHBG (nmol/L), and DHEA-S (mmol/L) pre 
and post, and the amount of change pre–post for each hormone parameter, are shown in Table 4. 
There was a highly statistically significant change in each parameter (all<0.001). While the 
majority of women showed a decrease in total T, four showed no change and 12 an increase. 
With FT, all but three women showed a decrease, and with SHBG, all but one woman showed an 
increase. For DHEA-S, levels decreased in all but 10 women. Spearman's correlation coefficients 
between change in DHEA-S and changes in total T and FT were rs=0.12, p=0.34, and rs=0.27, 
p=0.035, respectively. 
Table 4. 
Serum concentrations of total testosterone (T), percentage of free testosterone (%FT), free 
testosterone (FT), sex hormone binding globulin (SHBG), and dehydro-epiandrosterone-sulphate 
(DHEA-S) before starting on OCs (pre), after 3 months of OC use (post), and pre–post change; 
values are given as mean (SD) and range. 
Serum variable Pre Post Pre–post change 95% CI⁎ p† 
T (nmol/L) 1.21 (0.76) 0.75 (0.86) 0.46 (0.98) 0.21, 0.71 <0.001 
Range 0.1–3.7 0.1–6.0 −3.2–3.3   
% FT 2.45 (0.92) 0.78 (0.48) 1.67 (0.91) 1.43, 1.90 <0.001 
Serum variable Pre Post Pre–post change 95% CI⁎ p† 
Range 0.63–4.4 0.58–3.4 −3.5–0.22   
FT (pmol/L) 30.77 (28.6) 6.32 (10.4) 24.50 (28.75) 17.01, 31.89 <0.001 
Range 3.4–161.7 1.2–64.2 −157.0–8.58   
SHBG (nmol/L) 55.47 (31.8) 235.18 (104.8) −179.71 (92.1) −203.50, −155.92 <0.001 
Range 17–200 41.5–542 −2.0–484.0   
DHEA-S (mmol/L) 6.98 (3.51) 5.24 (3.00) 1.74 (2.74) 1.03, 2.44 < 0.001 
Range 1.52–17.0 0.95–15.20 −8.79–9.15   
⁎ CI=confidence interval. 
†p-value for Wilcoxon signed-ranks test. 
SHBG levels at baseline were compared for previous OC users (n=26) and never users (n=34) 
and were 58.9±36.1 and 53.5±28.7 nmol/l, respectively (t=0.64, p=0.52). 
 
Hypothesis 1. Adverse changes in sexuality will be positively related to the degree of reduction 
in T after starting OCs. 
 
We tested this hypothesis in two ways, one method incorporating change in the hormonal and 
behavioral variables from baseline, and the other utilizing the post levels of the sexuality and 
mood variables. 
 
For each of the mood and sexuality variables, women were divided into two groups: (1) negative 
change and (2) no change/positive change. For each variable the two groups were compared for 
degree of change in total T and FT. As shown in Table 5, reductions in total T and FT were not 
significantly greater in group 1 for any of the sexuality variables, for the BDI, or for the SEQ 





Comparison of change in total testosterone (T), free testosterone (FT), and dehydro-
epiandrosterone-sulphate (DHEA-S) in women reporting either negative change or no 
change/positive change in selected mood and sexuality variables; values are given as mean (SD). 
Variable Negative change No change/positive change p⁎ 
Frequency of sexual thoughts n=13 n=47†  
 T change (nmol/L) −0.754 (0.96) −0.283 (0.92) 0.17 
 FT change (pmol/L) −32.7 (40.6) −22.2 (24.7) 0.19 
 DHEA-S change (mmol/L) −1.80 (2.10) −1.72 (2.91) 0.96 
% of occasions “self” initiated n=14 n=41  
 T change (nmol/L) −0.626 (0.50) −0.033 (1.09) 0.08 
 FT change (pmol/L) −21.1 (17.2) −26.9 (33.0) 0.95 
 DHEA-S change (mmol/L) −1.67 (4.40) −1.88 (2.12) 0.67 
% of occasions pleasurable/enjoyable n=9 n=48  
 T change (nmol/L) −0.217 (0.29) −0.437 (1.05) 0.42 
 FT change (pmol/L) −15.2 (13.3) −27.0 (31.5) 0.40 
 DHEA-S change (mmol/L) −1.91 (3.20) −1.78 (2.77) 0.94 
% of occasions aroused/excited n=15 n=41  
 T change (nmol/L) −0.320 (0.78) −0.432 (1.04) 0.33 
 FT change (pmol/L) −31.1 (28.6) −22.9 (30.0) 0.13 
 DHEA-S change (mmol/L) −1.78 (2.31) −1.81 (3.00) 0.85 
BDI score n=22 n=36  
 T change (nmol/L) −0.452 (1.02) −0.374 (0.93) 0.99 
 FT change (pmol/L) −32.8 (40.9) −19.7 (17.8) 0.55 
 DHEA-S change (mmol/L) −1.47 (2.82) −1.89 (2.74) 0.71 
SEQ sexual summary score n=19 n=41  
Variable Negative change No change/positive change p⁎ 
 T change (nmol/L) −0.545 (0.90) −0.311 (0.97) 0.87 
 FT change (pmol/L) −27.4 (32.1) −23.1 (27.4) 0.99 
 DHEA-S change (mmol/L) −1.41 (2.21) −1.89 (2.96) 0.46 
⁎ p-value for Mann–Whitney test. 
† Due to missing data, the n varied from 56 to 60. 
With the second approach, the relationships between changes in total T, FT, and DHEA-S and 
the post levels of mood and sexuality were examined. As Table 6 shows, there was a significant 
correlation between frequency of sexual thoughts and changes in total T (p=0.02) and FT 
(p=0.006) and between percentage of occasions sexually aroused/excited and FT (p=0.03) but no 
other significant correlations with any of the other behavioral variables (only a subset of these 
are shown in Table 6). There were also no significant correlations between DHEA-S and any of 
the sexuality or mood variables. 
 
Table 6. 
Summary of correlations between changes in hormonal parameters and Post scores on selected 
mood and sexuality variables three months after starting Ocs. 
Variable⁎ rs p 
Frequency of sexual thoughts 
 T† change 0.295 0.02 
 FT‡ change 0.355 0.006 
 DHEA-S change −0.041 0.76 
% occasions “self” initiated 
 T change 0.249 0.06 
 FT change 0.008 0.95 
 DHEA-S change −0.047 0.73 
% occasions aroused/excited 
 T change 0.004 0.98 
Variable⁎ rs p 
 FT change 0.277 0.03 
 DHEA-S change 0.033 0.81 
BDI 
 T change −0.098 0.46 
 FT change −0.126 0.34 
 DHEA-S change 0.128 0.33 
⁎ Due to missing data, the n varied from 59 to 61. 
†T=total testosterone. 
‡FT=free testosterone. 
There was therefore some support for Hypothesis 1, suggesting a relationship between the degree 
of change in total T and FT and the frequency of sexual thoughts, and the degree of change in FT 
and sexual arousal/excitement, 3 months after starting on OCs. In addition, the correlation 
between change in total T and the proportion of occasions that were “self”-initiated was close to 
significant (p=0.06). 
 
Hypothesis 2. Relationships between T level and sexual interest will become more apparent 
when androgen levels fall below a certain “critical” threshold. 
 
This hypothesis was tested in two ways. Firstly, we examined the relationship between T levels 
and our measure of sexual interest at baseline (pre-OC) and after 3 months on OCs (post). If 
Hypothesis 2 is correct, there should be a stronger relationship between T levels and sexual 
interest when total T and FT levels are reduced (post) than before women have started on OCs. 
 
There were no significant correlations between total T or FT and sexual interest at baseline 
(frequency of sexual thoughts and total T, rs=−0.020; frequency of sexual thoughts and FT, 
rs=−0.072). After 3 months on OCs, correlations between total T and FT and frequency of sexual 
thoughts were slightly higher (total T, rs=0.143, p=0.28; FT, rs=0.130, p=0.33) but still not 
significant. 
 
In a second approach, we divided participants into three equal-sized groups based on their FT 
levels 3 months after starting OCs (post) as follows: low<2.19 pmol/L; medium=2.19–4.72 
pmol/L; high>4.72 pmol/L). Table 7 presents cross-tabulations of these three groups with IRSF 
ratings (post scores). After 3 months on the pill, the majority of women (n=44, 73.6%) reported 
thinking about sex at least several times a week (reported by n=40, 66.7% at baseline); however, 
of those who thought about sex less often than this, more (n=13, 81.2%) were in the “low” or 
“medium” FT groups than in the “high” FT group (n=3, 18.8%) (χ2=1.42, p=0.234). Similarly, 
there was a trend for the women who had initiated sex on 50% or more of the times that they had 
sexual activity with a partner to be progressively more likely to have higher FT scores (χ2 for 
linear trend=2.86, p=0.09). Of those women who initiated sex on 25% or fewer of the times that 
they had sexual activity with a partner, 73.7% (n=28) were in the “low” or “medium” FT group 
vs. only 26.3% (n=10) in the “high” FT group (χ2=1.32, p=0.251). For the variable “proportion 
of occasions sexually excited/aroused”, however, the association was in the reverse direction: 
women who reported a higher frequency of sexual acts in which they felt sexually aroused were 
more likely to be in the “low” or “medium” groups (n=37, 74.0%) than in the “high” FT group 
(n=13, 26.0%) (Fisher's exact test p=0.025). There was a significant linear trend among those 
who reported being sexually excited/aroused on 75% or more of occasions for them to be 
progressively less likely to be in the higher FT groups (χ2 for linear trend=5.18, p=0.023). There 
were no significant associations found for any of the other IRSF variables (frequency of sexual 
thoughts, proportion of occasions pleasurable/enjoyable, experienced orgasm, and frequency of 
masturbation). 
Table 7. 
Cross-tabulation of level of free T (FT) 3 months after starting OCs (low, medium, and high FT 
groups) by frequency of the IRSF variables sexual thoughts (post), initiation of sexual activity, 
and occasions sexually excited/aroused; values are given as n (% within FT group). 
 FT Group⁎ 
 
 Low (n=20) Medium (n=20) High (n=20) 
Frequency of sexual thoughts† 
 Once/month or less 0 (0) 4 (21) 1 (5) 
 1–4 times/month 5 (25) 4 (21) 2 (10) 
 Several times a week” to “at least once a day” 15 (75) 11 (58) 17 (85) 
Initiation of sexual activity‡ 
 FT Group⁎ 
 
 Low (n=20) Medium (n=20) High (n=20) 
 ⩽ 25% of occasions 15 (79) 13 (65) 10 (53) 
 ⩾ 50% of occasions 4 (21) 7 (35) 9 (47) 
Occasions sexually excited/aroused§ 
 ⩽ 50% of occasions 1 (5) 2 (10) 6 (32) 
 ⩾ 75% of occasions 19 (95) 18 (90) 13 (68) 
⁎ Low=< 2.19 pmol/L; medium=2.19 – 4.72 pmol/L; high>4.7 pmol/L. 
† Kruskal–Wallis χ2(2), 4.30, p=0.117; mean rank: low 31.25, medium 24.95, high 33.55. 
‡ χ2 (1) for linear trend=2.86, p=0.091. 
§ χ2 (1) for linear trend=5.18, p=0.023. 
In summary, we find limited support for Hypothesis 2. Frequency of sexual thoughts and self-
initiation of sexual activity with partners was lower in women who were in the “low” and 
“medium” FT groups. However, it was apparent that some women had a substantial reduction in 
FT but still experienced reasonable levels of sexual interest. 
 
4. Discussion 
Although reduced levels of FT have often been cited as the likely mechanism by which OCs 
might reduce sexual interest (Davis and Castaño, 2004), this is the first study that has 
systematically assessed mood and sexual functioning in women before starting on OCs and 
examined the relationship between OC-induced changes in T and negative behavioral effects. 
Consistent with previous research (Coenen et al., 1996), mean serum levels of total T, FT, and 
DHEA-S decreased significantly and levels of SHBG increased in women after starting on OCs, 
although the extent of the reduction was variable. As our sample included women who had 
previously used OCs (43.3%) as well as first-time users, we were able to compare SHBG levels 
in these two groups at baseline (i.e., pre OC use). In contrast with a recent report of persistently 
elevated SHBG levels in women who had discontinued OC use (Panzer et al., 2006), the SHBG 
levels of women who were previous OC users and the “never user” group did not differ. 
 
The primary aim of this study was to look at whether changes in androgen parameters from 
baseline to 3 months of OC use were related to changes in sexual interest or response. We found 
some support for our first hypothesis, that negative changes in sexuality and/or mood would be 
related to the reduction in total T and FT after starting OCs and this was only evident from our 
measures of sexual interest (the frequency of sexual thoughts), and sexual arousal (the frequency 
of feeling aroused/excited during sexual activity) reported by women 3 months after starting 
OCs. There was no evidence of T reduction affecting enjoyment of sexual activity with a partner. 
There was also no relationship between negative mood and changes in T, FT, or DHEA-S. 
 
There was limited evidence for our second hypothesis, that relationships between T levels and 
sexual behavior would become more pronounced when levels of T are reduced below a certain 
critical threshold. Low frequency of sexual thoughts and self-initiation of sexual activity with a 
partner was more likely in women who were at the lower end of the range in FT levels. However, 
in so far as we found an adverse sexual effect of reduced T levels in women taking OCs, this was 
only relevant to sexual interest and not to the woman's sexual response and enjoyment during 
sexual activity with a partner. This would be consistent with the idea that androgens in women 
primarily affect sexual “motivation” and not response during sexual activity such as arousal and 
orgasm (Sherwin et al., 1985). It is also important to keep in mind that psychological and 
relationship factors will interact with possible hormonal mechanisms in influencing a woman's 
response to starting OCs. 
 
Although the mean ratings on mood and sexuality measures pre-post OC suggested very little 
change, this obscured the fact that for all measures, in addition to a subgroup showing no change, 
similar proportions of women showed either positive or negative changes. Without a placebo 
control, it is difficult to know to what extent such variability would occur over a 3-month period 
even if women were not using hormonal contraception. However, it is noteworthy that even in 
controlled studies, this pattern of marked variability in response to OCs has been recognized for 
some time (Cullberg, 1972; Bancroft and Sartorius, 1990). In fact, the most consistent finding in 
the literature addressing the impact of OCs on mood and sexual interest has been the marked 
variability in women's responses to the pill. 
 
It is clear that substantial reduction in FT can occur in many women without impairment of 
sexual interest or response. It remains possible, however, that such reduction could have an 
impact in a minority of women who are more sensitive to the behavioral effects of T. Given that 
we have no idea what proportion of women would come into our postulated category of 
“testosterone sensitive”, if indeed such a category exists, there is a need to identify predictors or 
markers of such T sensitivity. Unfortunately, the sample size in this study was too small for this 
purpose. Limited attention has been paid to predictors of negative mood change. Early studies 
suggested that women who had a previous history of depression might be more likely to become 
depressed after starting on OCs (Lewis and Hoghughi, 1969). Cullberg (1972), in a study 
comparing differing progestagen doses, found that women with a history of premenstrual 
irritability had more negative reactions when taking “low-progestagen” OCs. Bancroft et al. 
(1987) randomly assigned women to either a combined or a triphasic OC. In women with high 
premenstrual mood change before starting the pill, those who took the triphasic OC showed 
significantly lower mood and “sexual feelings” than those who took the combined pill. Another 
possible marker of T sensitivity that would merit investigation is the experience of higher sexual 
interest around ovulation, when T levels increase. Future research involving larger samples of 
women and assessment of a wide range of potential markers of T sensitivity is required. 
 
An alternative approach is to evaluate the effects of T administration on women with adverse 
sexual side effects with OCs. To date only one placebo-controlled study has attempted this 
(Bancroft et al., 1980). Of 15 women reporting sexual problems with OC use, only one woman 
showed a clear positive response to exogenous androstenedione (Bancroft et al., 1980). 
 
Are there other possible hormonal mechanisms that might underlie negative effects of OCs on 
mood or sexuality? Early studies, involving high-dose OCs, compared women using pills varying 
in the dose of progestagen but the findings were inconsistent; in one study, higher progestagen 
dosages (Grant and Pryse-Davies, 1968) and in another, lower progestagen formulations (Kutner 
and Brown, 1972) were associated with depression and loss of libido. In a more recent placebo-
controlled study of combined and progestagen-only pills (POP), the POP was associated with no 
negative effects on sexuality and some improvement in mood (Graham et al., 1995); however, 
the combined OC, that adversely affected sexuality in a subgroup of women, contained a higher 
dose of progestagen than the POP. 
 
Our study had several limitations. The small sample size and the single blood sample taken 
before starting OCs and after 3 months of pill use meant there would have been many sources of 
random error, increasing the total amount of random variability present in the data. Our sample 
involved young, predominantly unmarried women; the findings may not be generalizable to 
other populations of women. There was limited assessment of mood, with only severity of 
depressive symptoms assessed. Future studies should use broader measures of mood that 
incorporate positive mood states/well-being. 
 
In conclusion, it appears that a substantial proportion of women who take OCs experience a 
marked decline in serum androgen levels without adverse sexual effects. What distinguishes 
women who experience negative sexual side effects from those who do not remains unexplained 
and a question of crucial importance for future research. 
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